
June 17 (Reuters) - Ventyx Biosciences Inc VTYX.O:
VENTYX BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE DATA FROM ITS PHASE 2A SAFETY AND BIOMARKER TRIAL EVALUATING VTX3232 IN PATIENTS WITH EARLY-STAGE PARKINSON’S DISEASE
VENTYX BIOSCIENCES INC - VTX3232 STUDY MEETS PRIMARY GOAL OF SAFETY AND TOLERABILITY
VENTYX BIOSCIENCES INC - VTX3232 SHOWS SIGNIFICANT REDUCTIONS IN NLRP3-RELATED BIOMARKERS
VENTYX BIOSCIENCES INC - VTX3232 PHASE 2 TRIAL IN OBESITY AND CARDIOMETABOLIC RISK FACTORS RESULTS EXPECTED H2 2025